4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-14-000079
$BHCCIK 0000885590operating
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 4:37 PM ET
Size
6.4 KB
Accession
0000885590-14-000079
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Award
Restricted Share Units
2014-12-01+100,000→ 100,000 total→ Common Shares, no par value (300,000 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit ("RSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $136.41 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on September 1, 2016, 50% on December 1, 2016 and 25% on March 1, 2017, with early vesting possible at higher TSR levels.
- [F3]Represents the maximum number of Common Shares that may be issued under the RSU award. See note (2).
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 4:37 PM ET
- Size
- 6.4 KB